Acute myeloid leukemia (AML) is characterized by impaired differentiation and indefinite
proliferation of abnormal myeloid progenitors. Although differentiating agents were deemed …

The AML treatment landscape has significantly changed in recent years with the approval of
targeted therapies in the front-line and relapsed/refractory settings, including inhibitors of …

In MLL1-rearranged AML (MLL1-r), the MLL1 fusion protein (MLLFP) causes dysregulated
expression of HOXA9, MEIS1, PBX3, MEF2C and CDK6 [1, 2]. HOXA9 and its co-factor …

Papain-like cysteine peptidases form a big and highly diverse superfamily of proteins
involved in many important biological functions, such as protein turnover, deubiquitination …

Adhesion molecules play essential roles in the homeostatic regulation and malignant
transformation of hematopoietic cells. The dysregulated expression of adhesion molecules …

Aberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged,
NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and …

The direct targeting of chromatin-associated proteins is increasingly recognized as a
potential therapeutic strategy for the treatment of cancer. In this review, we discuss a …

KMT2A (alias: mixed-lineage leukemia [MLL]) gene mapping on chromosome 11q23
encodes the lysine-specific histone N-methyltransferase 2A and promotes transcription by …

Genetic lesions of IKZF1 are frequent events and well-established markers of adverse risk in
acute lymphoblastic leukemia. However, their function in the pathophysiology and impact on …

Menin interacts with oncogenic MLL1-fusion proteins, and small molecules that disrupt these
associations are in clinical trials for leukemia treatment. By integrating chromatin-focused …